Ocrevus 300mg (IV) Ocrelizumab

Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of:

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Primary progressive MS, in adults.

Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]